China Localizes Manufacturing Relenza, Tamiflu; Drugs Pending Marketing, Manufacturing Approval
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Although China has not reported a case of swine flu, except for two suspected cases in Hong Kong, the government has taken actions to prevent the virus from entering China and to prepare for a potential outbreak, including quarantining people who arrived from Mexico suspected of exposure to swine flu
You may also be interested in...
China State FDA Grants Simcere Record Fast-track Approval To Market Generic Relenza
SHANGHAI - Nanjing-based Simcere announced during the Chinese New Year celebration that the company received approval from China's State FDA to manufacture and market a generic version of GlaxoSmithKline's antiviral Relenza (zanamivir)
China State FDA Grants Simcere Record Fast-track Approval To Market Generic Relenza
SHANGHAI - Nanjing-based Simcere announced during the Chinese New Year celebration that the company received approval from China's State FDA to manufacture and market a generic version of GlaxoSmithKline's antiviral Relenza (zanamivir)
China Clears GSK’s Relenza For Clinical Trials By Chinese Firms
China's State FDA has cleared for clinical testing GlaxoSmithKline's Relenza (zanamivir) antiviral for treating avian flu. The drug is being developed under a licensing agreement in China between Nanjing Simcere Dongyuan Pharmaceutical and Nanjing EffactPharm Drug Development along with the Shanghai Institute of Materia Medica. Simcere has marketing rights from GSK in China, Indonesia, Thailand, Vietnam and other developing countries. (Click here for more